BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.

[1]  D. Muzny,et al.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. , 2014, Blood.

[2]  Larissa V Furtado,et al.  High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. , 2014, Blood.

[3]  A. Stenzinger,et al.  Potential clinical implications of BRAF mutations in histiocytic proliferations , 2014, Oncotarget.

[4]  J. Ryu,et al.  BRAF V600E Expression in Langerhans Cell Histiocytosis: Clinical and Immunohistochemical Study on 25 Pulmonary and 54 Extrapulmonary Cases , 2014, The American journal of surgical pathology.

[5]  A. Salajegheh,et al.  B-Raf mutation: a key player in molecular biology of cancer. , 2013, Experimental and molecular pathology.

[6]  Paul S. Meltzer,et al.  High prevalence of MAP2K1 mutations in variant and IGHV4-34 expressing hairy-cell leukemia , 2013, Nature Genetics.

[7]  Yuri E Nikiforov,et al.  Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. , 2013, Chest.

[8]  K. Aldape,et al.  Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. , 2013, The Journal of molecular diagnostics : JMD.

[9]  M. Copin,et al.  High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. , 2012, Blood.

[10]  A. Stenzinger,et al.  BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. , 2012, Blood.

[11]  H. Kantarjian,et al.  Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. , 2012, American journal of clinical pathology.

[12]  F. Fraternali,et al.  B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease , 2012, PloS one.

[13]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[15]  H. Zentgraf,et al.  Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.

[16]  W. Hahn,et al.  Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.

[17]  W. Sellers,et al.  MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.

[18]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[19]  Jingwu Xie,et al.  MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas , 2009, Cell cycle.

[20]  M. Belvin,et al.  Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. , 2009, Cancer research.

[21]  Li Ding,et al.  Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.

[22]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[23]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[24]  T. Colby,et al.  Pulmonary Langerhans' Cell Histiocytosis: Molecular Analysis of Clonality , 2001, The American journal of surgical pathology.

[25]  D. Gilliland,et al.  Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. , 1994, The New England journal of medicine.

[26]  L. Buluwela,et al.  Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis , 1994, The Lancet.

[27]  R. Levinsky,et al.  SPONTANEOUS REMISSION OF MULTI-SYSTEM HISTIOCYTOSIS X , 1984, The Lancet.

[28]  Amy Young,et al.  Ras signaling and therapies. , 2009, Advances in cancer research.

[29]  T. McLean,et al.  Spontaneous regression of langerhans cell histiocytosis in a neonate with multiple bony lesions. , 2008, Journal of pediatric hematology/oncology.

[30]  R. Arceci,et al.  Biology of Langerhans cells and Langerhans cell histiocytosis. , 2006, International review of cytology.